ibritumomab tiuxetan + rituximab

Ibritumomab tiuxetan + rituximab is a combination therapy used primarily for the treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin lymphoma (NHL), including cases that are refractory to prior treatments. Ibritumomab tiuxetan is a murine IgG1 monoclonal antibody covalently bound to the chelating agent tiuxetan and radiolabeled with yttrium-90. It targets the CD20 antigen on B lymphocytes, delivering targeted radiation that induces cell death through beta particle emission. The antibody also mediates immune responses such as antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. Rituximab, a chimeric monoclonal anti-CD20 antibody, is administered prior to ibritumomab tiuxetan to deplete circulating B cells and enhance targeting of malignant cells[1][2][3][6][7]. This regimen was developed by IDEC Pharmaceuticals (now part of Biogen) and has been marketed under the brand name Zevalin.

Brand names

ZevalinRituxan (for rituximab)Truxima (for rituximab)

Other names

ibritumomabYttrium 90 ibritumomab tiuxetanYttrium90 ibritumomab tiuxetanYttrium-90 ibritumomab tiuxetan